Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing
Clinical Pharmacology & Therapeutics2015Vol. 98(1), pp. 19–24
Citations Over TimeTop 1% of 2015 papers
Kelly A. Birdwell, Brian S. Decker, JM Barbarino, JF Peterson, Catherine M. Stein, Wolfgang Sadée, Daqing Wang, Alexander A. Vinks, Yijing He, JJ Swen, JS Leeder, RHN van Schaik, KE Thummel, Teri E. Klein, KE Caudle, IAM MacPhee
Abstract
Tacrolimus is the mainstay immunosuppressant drug used after solid organ and hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and intermediate metabolizers) generally have decreased dose-adjusted trough concentrations of tacrolimus as compared with those who are CYP3A5 nonexpressers (poor metabolizers), possibly delaying achievement of target blood concentrations. We summarize evidence from the published literature supporting this association and provide dosing recommendations for tacrolimus based on CYP3A5 genotype when known (updates at www.pharmgkb.org).
Related Papers
- → CYP3A5 Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted Patients(2020)22 cited
- A systematic review and meta-analysis recite the efficacy of Tacrolimus treatment in renal transplant patients in association with genetic variants of CYP3A5 gene.(2023)
- Polymorphisms in CYP3A5*3 and MDR1, and haplotype modulate response to plasma levels of tacrolimus in Chinese renal transplant patients.(2011)
- → Influence of CYP3A5 polymorphism on tacrolimus blood concentrations in renal transplant patients(2005)8 cited
- Influence of CYP3A5 polymorphism on tacrolimus blood concentrations in renal transplant patients(2005)